Mylan Drug Patent Portfolio
Mylan owns 3 orange book drugs protected by 8 US patents Given below is the list of Mylan's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9345772 | Liquid levothyroxine formulations | 27 Feb, 2035 | Active |
| US8147852 | Modified azole compounds as antifungal and antibacterial agents | 30 Mar, 2028 | Active |
| US6579981 | Antiviral guanine derivatives | 17 Jun, 2020 | Expired |
| US6469015 | Pharmaceutical formulation | 22 Oct, 2019 | Expired |
| US5840763 | Treatment of a latent infection of herpes viruses | 01 Sep, 2015 | Expired |
| US5916893 | Treatment of a latent infection of herpes virus | 01 Sep, 2015 | Expired |
| US5866581 | Penciclovir for the treatment of post therapeutic neuralgia | 04 Oct, 2014 | Expired |
| US6124304 | Penciclovir for the treatment of zoster associated pain | 04 Oct, 2014 | Expired |
Latest Legal Activities on Mylan's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mylan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Sep, 2023 | US8147852 |
|
Email Notification
Critical
| 16 May, 2022 | US8147852 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 May, 2022 | US8147852 |
|
Correspondence Address Change
Critical
| 13 May, 2022 | US8147852 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 26 Sep, 2019 | US8147852 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Sep, 2019 | US8147852 |
|
Email Notification
Critical
| 14 Nov, 2016 | US8147852 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Nov, 2016 | US8147852 |
|
Correspondence Address Change
Critical
| 10 Nov, 2016 | US8147852 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 06 May, 2016 | US8147852 |
|
Email Notification
Critical
| 06 May, 2016 | US8147852 |
|
Correspondence Address Change
Critical
| 05 May, 2016 | US8147852 |
| Post Issue Communication - Certificate of Correction | 19 Jun, 2012 | US8147852 |
|
Recordation of Patent Grant Mailed
Critical
| 03 Apr, 2012 | US8147852 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 03 Apr, 2012 | US8147852 |
Mylan's Drug Patent Litigations
Mylan's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 14, 2000, against patent number US6579981. The petitioner , challenged the validity of this patent, with JARVEST et al as the respondent. Click below to track the latest information on how companies are challenging Mylan's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8147852 | November, 2010 |
Decision
(08 Aug, 2011)
| Marcel Borgers et al | |
| US6579981 | January, 2000 |
Decision
(26 Sep, 2002)
| JARVEST et al | |
| US6579981 | January, 2000 |
Decision
(04 Jul, 1776)
| JARVEST et al | |
Mylan's Family Patents
Mylan Drug List
Given below is the complete list of Mylan's drugs and the patents protecting them.
1. Denavir
Denavir is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6579981 | Antiviral guanine derivatives |
17 Jun, 2020
(4 years ago)
| Expired |
| US6469015 | Pharmaceutical formulation |
22 Oct, 2019
(5 years ago)
| Expired |
| US5840763 | Treatment of a latent infection of herpes viruses |
01 Sep, 2015
(9 years ago)
| Expired |
| US5916893 | Treatment of a latent infection of herpes virus |
01 Sep, 2015
(9 years ago)
| Expired |
| US5866581 | Penciclovir for the treatment of post therapeutic neuralgia |
04 Oct, 2014
(10 years ago)
| Expired |
| US6124304 | Penciclovir for the treatment of zoster associated pain |
04 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Denavir's drug page
2. Ermeza
Ermeza is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9345772 | Liquid levothyroxine formulations |
27 Feb, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ermeza's drug page
3. Vusion
Vusion is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8147852 | Modified azole compounds as antifungal and antibacterial agents |
30 Mar, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vusion's drug page